MN-DIGI-INTERNATIONAL
19.1.2023 10:01:43 CET | Business Wire | Press release
Digi International (NASDAQ: DGII, www.digi.com), a leading global provider of Internet of Things (IoT) solutions, connectivity products, and services, today launched two Digi ConnectCore® software service offerings – Digi ConnectCore® Cloud Services and Digi ConnectCore® Security Services. The offerings provide greater manageability and security for devices developed with Digi’s complete line of ConnectCore system-on-modules (SOMs).
Today’s OEMs – and their customers – need end-to-end hardware/software solutions to actively manage their device portfolios, gather data from devices in the field and deliver real-time updates and security patches as needed. Digi ConnectCore Cloud Services deliver the manageability they need to enable secure, over-the-air (OTA) software updates, access device data, and perform remote diagnostics, command and control. Digi ConnectCore Cloud Services also provide API access enabling custom applications and remote dashboards empowering OEMs to create innovative customer service plans.
Digi ConnectCore Security Services enable OEMs to maintain the security of products during their entire lifecycle and empower device makers to solve the ongoing challenge of keeping products secure after release. The services include the analysis and monitoring of a custom software bill of material (SBOM) and binary image running on Digi ConnectCore SOMs for security risks and vulnerabilities. To help remediate identified issues, the services provide a curated vulnerability report highlighting critical concerns, a security software layer including patches for common vulnerabilities, and consulting services.
Together, the two services provide a comprehensive software foundation that, in conjunction with Digi’s family of ConnectCore system-on-modules, enable OEMs to deliver highly secure, connected IoT products with increased product quality, improved technical support, and a stronger end-customer experience. Both Digi ConnectCore services support the entire family of Digi ConnectCore systems-on-modules.
Digi, an ST Authorized Partner, also announced the general availability of its Digi ConnectCore MP157 system-on-module (SOM), which leverages the STMicroelectronics STM32MP157C microprocessor and has a fully integrated dual-band Wi-Fi/BT interface. Now available in developer kits from Digi’s global channel partners, the tiny ConnectCore MP15 is ideal for handheld products with cameras and/or displays such as medical devices, environmental test equipment, industrial-grade human machine interfaces, or headless devices such as EV charging stations and renewable-energy controllers. By addressing the need to build intelligent, connected, and secure wireless products for healthcare, transportation, and industrial sectors, Digi ConnectCore MP1 SOMs offer unparalleled flexibility and scalability. The highly integrated solution includes a complete set of development tools, design support, software, and security building blocks to speed time to market.
“Digi ConnectCore Services continue our mission to reduce the complexity OEMs are facing with implementing full end-to-end industrial IoT solutions and simplify device security and management for our customers,” said Andreas Burghart, Senior Product Manager for Digi’s Embedded division. “The combination of innovative SOM hardware and software, cloud-based services, and comprehensive security improve our customers’ ability to deliver and manage secure, cost-effective solutions and extend our leadership in embedded systems.”
“Using the Digi ConnectCore MP1 SOM with integrated wireless capabilities reduces the design complexity significantly for OEMs, especially for companies that have designed products using the STM32 microcontroller portfolio,” said Jean-Philippe Moreno, Product Marketing Manager, STMicroelectronics. “For developers now moving into the higher performance microprocessor space, the Digi SOM solution reduces the risk significantly and helps to make this transition.”
For more information, visit Digi at the STMicroelectronics booth #447 at the IoT Solutions World Congress, Jan. 31–Feb. 2, 2023.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005014/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom